Nanozyme-based tumour catalytic therapy has attracted widespread attention in recent years, but the therapeutic efficacy is limited due to the trapping of hydroxyl radicals (˙OH) by endogenous glutathione (GSH) in the tumour microenvironment (TME). Zr/Ce-MOFs/DOX/MnO 2 is constructed in this work to serve as a new kind of nanozyme for combination chemotherapy and catalytic treatment. Zr/Ce-MOFs can produce ˙OH in a mimic TME, and the MnO 2 on the surface could deplete the GSH, further promoting the ˙OH generation. The pH/GSH dual stimulation accelerates the release of anticancer drug doxorubicin (DOX) in tumour tissue for enhanced tumour chemotherapy. Moreover, Mn 2+ produced by the reaction of Zr/Ce-MOFs/DOX/MnO 2 and GSH can be used as the contrast agent for T 1 -MRI. The potential antitumour effect of Zr/Ce-MOFs/DOX/MnO 2 is demonstrated by in vitro and in vivo cancer treatment tests. This work thus provides a new nanozyme-based platform for enhanced combination chemotherapy and catalytic treatment for tumours.
Keyphrases
- pet imaging
- locally advanced
- metal organic framework
- fluorescent probe
- magnetic resonance imaging
- stem cells
- squamous cell carcinoma
- computed tomography
- drug delivery
- wastewater treatment
- contrast enhanced
- energy transfer
- risk assessment
- working memory
- climate change
- quantum dots
- rectal cancer
- mesenchymal stem cells
- adverse drug
- drug induced
- crystal structure
- pet ct